Annual changes in BMD and bone turnover markers during 5 years after a single administration of zoledronate
| Time (mo) | Zolendronate dose; mean % difference from placebo (95% CI)* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoledronate 1 mg | Zoledronate 2.5 mg | Zoledronate 5 mg | ||||||||||
| Spine BMD | Total hip BMD | β-CTX | P1NP | Spine BMD | Total hip BMD | β-CTX | P1NP | Spine BMD | Total hip BMD | β-CTX | P1NP | |
| 12 | 3.6 (1.8 to 5.3) | 2.7 (1.7 to 3.7) | −45 (−56 to −34) | −44 (−57 to −30) | 4.0 (2.2 to 5.8) | 3.7 (2.6 to 4.7) | −69 (−81 to −57) | −60 (−74 to −46) | 3.9 (2.1 to 5.6) | 3.5 (2.5 to 4.5) | −74 (−85 to −63) | −66 (−80 to −52) |
| 24 | 5.0 (3.0 to 7.0) | 2.6 (1.3 to 3.9) | −20 (−34 to −6) | −19 (−33 to −5) | 5.7 (3.7 to 7.7) | 4.1 (2.9 to 5.4) | −47 (−61 to −34) | −32 (−45 to −19) | 5.7 (3.7 to 7.6) | 4.7 (3.4 to 5.9) | −53 (−66 to −40) | −31 (−44 to −19) |
| 36 | 2.8 (0.1 to 5.5) | 2.1 (0.6 to 3.7) | −7 (−30 to 15) | −23 (−50 to 5) | 4.1 (1.4 to 6.8) | 4.5 (2.9 to 6.1) | −38 (−61 to −15) | −38 (−66 to −11) | 5.2 (2.5 to 7.9) | 5.2 (3.7 to 6.8) | −42 (−65 to −19) | −30 (−58 to −3) |
| 48 | 2.5 (−0.2 to 5.3) | 1.9 (0.4 to 3.5) | −10 (−27 to 6) | −19 (−43 to 5) | 4.0 (1.2 to 6.8) | 3.6 (2.1 to 5.2) | −24 (−40 to −8) | −25 (−49 to −1) | 5.6 (2.9 to 8.3) | 5.2 (3.7 to 6.7) | −29 (−44 to −13) | −30 (−53 to −7) |
| 60 | 2.0 (−1.1 to 5.0) | 1.8 (−0.1 to 3.8) | −2 (−25 to 21) | −6 (−26 to 14) | 2.2 (−1.0 to 5.4) | 2.8 (0.8 to 4.8) | −19 (−43 to 5) | −10 (−31 to 10) | 5.1 (2.2 to 8.1) | 5.4 (3.5 to 7.3) | −27 (−49 to −4) | −22 (−41 to −3) |
Note: β-CTX = β-C-terminal telopeptide of type I collagen, BMD = bone mineral density, CI = confidence interval, P1NP = procollagen type 1 N-terminal propeptide.
↵* A negative value indicates a lower value in the zoledronate group.